CERT
Certara, Inc. NASDAQ Listed Dec 11, 2020$6.31
Mkt Cap $967.5M
52w Low $5.19
12.9% of range
52w High $13.88
50d MA $6.26
200d MA $9.10
P/E (TTM)
-618.0x
EV/EBITDA
14.7x
P/B
0.9x
Debt/Equity
0.0x
ROE
-0.1%
P/FCF
14.9x
RSI (14)
—
ATR (14)
—
Beta
1.62
50d MA
$6.26
200d MA
$9.10
Avg Volume
3.8M
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
100 Overlook Center · Princeton, NJ 08540 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | 0.11 | 0.09 | -18.2% | 6.80 | -1.5% | +4.1% | +3.7% | +6.5% | +8.1% | +5.1% | — |
| Nov 6, 2025 | AMC | 0.11 | 0.14 | +27.3% | 11.27 | -1.9% | -23.1% | -23.5% | -23.9% | -26.5% | -25.4% | — |
| Aug 6, 2025 | AMC | 0.10 | 0.07 | -30.0% | 9.53 | +7.0% | +18.2% | +14.8% | +9.9% | +12.8% | +17.2% | — |
| May 5, 2025 | AMC | 0.13 | 0.14 | +7.7% | 12.78 | +2.6% | -11.0% | -10.3% | -7.1% | -6.3% | -5.1% | — |
| Feb 26, 2025 | AMC | 0.13 | 0.15 | +15.4% | 12.33 | +6.1% | +0.6% | -2.8% | -3.2% | -3.9% | -3.4% | — |
| Nov 6, 2024 | AMC | 0.11 | 0.13 | +18.2% | 10.91 | -1.2% | +0.7% | +1.1% | -0.2% | -2.8% | -1.8% | — |
| Aug 6, 2024 | AMC | 0.11 | 0.07 | -36.4% | 15.08 | -10.5% | -13.6% | -13.3% | -17.0% | -20.4% | -17.4% | — |
| May 7, 2024 | AMC | 0.10 | 0.10 | +0.0% | 17.66 | -4.6% | -7.4% | -3.4% | -3.7% | -5.7% | -7.0% | — |
| Feb 29, 2024 | AMC | 0.11 | 0.09 | -18.2% | 16.88 | +5.2% | +8.4% | +11.8% | +10.2% | +12.9% | +15.2% | — |
| Nov 8, 2023 | AMC | 0.11 | 0.11 | +0.0% | 12.48 | +5.6% | +1.4% | +8.2% | +4.3% | +16.1% | +18.0% | — |
| Aug 9, 2023 | AMC | 0.13 | 0.12 | -7.7% | 17.92 | -13.5% | -7.6% | -7.0% | -4.1% | -5.7% | -7.4% | — |
| May 8, 2023 | AMC | 0.12 | 0.12 | +0.0% | 23.42 | -8.9% | -10.7% | -10.5% | -10.4% | -13.2% | -13.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 13 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $5.55 | $5.53 | -0.4% | +4.3% | +4.9% | +10.8% | +11.0% | +12.1% |
| Mar 6 | Barclays | Downgrade | Overweight → Equal Weight | — | $7.15 | $6.92 | -3.2% | -1.3% | -1.5% | -3.1% | -6.9% | -8.3% |
| Feb 27 | Barclays | Maintains | Overweight → Overweight | — | $6.80 | $6.70 | -1.5% | +4.1% | +3.7% | +6.5% | +8.1% | +5.1% |
| Jan 8 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $9.49 | $9.50 | +0.1% | +1.9% | -1.7% | -1.1% | -3.6% | -1.8% |
| Jan 6 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $9.04 | $9.43 | +4.3% | +5.9% | +5.0% | +7.0% | +3.2% | +3.9% |
| Dec 18 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $8.86 | $8.87 | +0.1% | +0.2% | +2.4% | +2.8% | +1.2% | +0.6% |
| Dec 15 | Barclays | Maintains | Overweight → Overweight | — | $8.58 | $8.66 | +0.9% | +1.9% | +0.9% | +3.3% | +3.5% | +5.7% |
| Dec 12 | Stephens & Co. | Maintains | Overweight → Overweight | — | $8.81 | $8.79 | -0.2% | -2.6% | -0.8% | -1.7% | +0.6% | +0.8% |
| Nov 7 | Barclays | Maintains | Overweight → Overweight | — | $11.27 | $11.06 | -1.9% | -23.1% | -23.5% | -23.9% | -26.5% | -25.4% |
| Oct 8 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $12.93 | $13.23 | +2.3% | +0.5% | +0.1% | -8.3% | -5.3% | -8.0% |
| Oct 2 | Barclays | Maintains | Overweight → Overweight | — | $13.37 | $13.48 | +0.8% | +1.7% | -2.2% | +0.6% | -3.3% | -2.8% |
| Aug 7 | UBS | Maintains | Buy → Buy | — | $9.53 | $10.20 | +7.0% | +18.2% | +14.8% | +9.9% | +12.8% | +17.2% |
| Jul 14 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $11.09 | $11.03 | -0.5% | +0.5% | -6.1% | -6.1% | -5.0% | -8.9% |
| May 8 | Barclays | Upgrade | Equal Weight → Overweight | — | $11.46 | $12.17 | +6.2% | +3.6% | +4.5% | +5.8% | +5.9% | +2.3% |
| May 6 | JMP Securities | Maintains | Market Perform → Market Perform | — | $12.78 | $13.11 | +2.6% | -11.0% | -10.3% | -7.1% | -6.3% | -5.1% |
| Apr 16 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $13.88 | $14.01 | +0.9% | -2.5% | +1.9% | +4.3% | +4.1% | +2.7% |
| Apr 11 | Baird | Maintains | Neutral → Neutral | — | $10.51 | $11.84 | +12.7% | +22.8% | +37.0% | +32.1% | +28.7% | +34.6% |
| Apr 10 | Barclays | Maintains | Equal Weight → Equal Weight | — | $9.73 | $9.49 | -2.5% | +8.0% | +32.7% | +48.0% | +42.7% | +39.1% |
| Feb 28 | Barclays | Maintains | Equal Weight → Equal Weight | — | $12.40 | $12.21 | -1.5% | -3.4% | -3.7% | -4.4% | -4.0% | -6.3% |
| Feb 27 | Stephens & Co. | Maintains | Overweight → Overweight | — | $12.33 | $13.08 | +6.1% | +0.6% | -2.8% | -3.2% | -3.9% | -3.4% |
| Nov 7 | Barclays | Maintains | Equal Weight → Equal Weight | — | $10.91 | $10.78 | -1.2% | +0.7% | +1.1% | -0.2% | -2.8% | -1.8% |
| Nov 5 | Baird | Maintains | Neutral → Neutral | — | $10.25 | $10.12 | -1.3% | +0.6% | +6.4% | +7.2% | +7.6% | +6.2% |
| Oct 15 | Barclays | Maintains | Equal Weight → Equal Weight | — | $11.24 | $11.19 | -0.4% | -0.3% | -0.2% | +2.9% | +1.5% | -0.4% |
| Sep 27 | UBS | Upgrade | Neutral → Buy | — | $10.70 | $11.59 | +8.3% | +9.8% | +9.4% | +6.1% | +6.3% | +2.7% |
| Aug 7 | Baird | Maintains | Neutral → Neutral | — | $15.08 | $13.49 | -10.5% | -13.6% | -13.3% | -17.0% | -20.4% | -17.4% |
| Aug 7 | UBS | Maintains | Neutral → Neutral | — | $15.08 | $13.49 | -10.5% | -13.6% | -13.3% | -17.0% | -20.4% | -17.4% |
| Jul 11 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $13.88 | $14.01 | +0.9% | +8.9% | +9.4% | +12.8% | +18.9% | +19.2% |
| Jun 28 | Barclays | Maintains | Equal Weight → Equal Weight | — | $13.65 | $13.74 | +0.7% | +1.5% | -0.1% | +0.1% | +1.4% | +4.2% |
| Apr 10 | KeyBanc Capital Markets | Upgrade | Sector Weight → Overweight | — | $18.51 | $18.20 | -1.7% | -0.3% | -0.3% | -4.5% | -5.8% | -7.8% |
| Mar 1 | UBS | Maintains | Neutral → Neutral | — | $16.88 | $17.75 | +5.2% | +8.4% | +11.8% | +10.2% | +12.9% | +15.2% |
| Mar 1 | Jefferies | Maintains | Hold → Hold | — | $16.88 | $17.75 | +5.2% | +8.4% | +11.8% | +10.2% | +12.9% | +15.2% |
| Jan 25 | Barclays | Maintains | Equal Weight → Equal Weight | — | $16.10 | $16.35 | +1.6% | +0.2% | +3.2% | +2.5% | +1.9% | +0.4% |
| Oct 11 | Stephens & Co. | Maintains | Overweight → Overweight | — | $14.36 | $14.38 | +0.1% | -0.6% | -3.4% | -4.3% | -2.8% | -1.9% |
| Aug 22 | Jefferies | Downgrade | Buy → Hold | — | $16.11 | $15.45 | -4.1% | -2.7% | -0.7% | -1.4% | +0.1% | -1.2% |
| Aug 15 | BofA Securities | Maintains | Buy → Buy | — | $17.19 | $17.09 | -0.6% | -1.7% | -3.4% | -5.6% | -6.7% | -6.3% |
| Aug 11 | Barclays | Maintains | Equal Weight → Equal Weight | — | $16.55 | $16.47 | -0.5% | +0.7% | +3.9% | +2.1% | +0.3% | -1.9% |
| Aug 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $17.92 | $15.50 | -13.5% | -7.6% | -7.0% | -4.1% | -5.7% | -7.4% |
| Aug 10 | William Blair | Downgrade | Outperform → Market Perform | — | $17.92 | $15.50 | -13.5% | -7.6% | -7.0% | -4.1% | -5.7% | -7.4% |
| Aug 10 | Credit Suisse | Maintains | Outperform → Outperform | — | $17.92 | $15.50 | -13.5% | -7.6% | -7.0% | -4.1% | -5.7% | -7.4% |
| Jul 27 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $19.26 | $19.36 | +0.5% | -3.2% | -0.5% | +1.1% | -0.8% | -3.4% |
| Apr 4 | Barclays | Downgrade | Overweight → Equal Weight | — | $23.57 | $23.74 | +0.7% | -2.0% | -2.9% | -2.4% | -2.1% | -1.9% |
| Apr 3 | Barclays | Downgrade | Overweight → Equal Weight | — | $24.11 | $23.12 | -4.1% | -2.2% | -4.2% | -5.1% | -4.6% | -4.3% |
| Mar 27 | Credit Suisse | Maintains | Outperform → Outperform | — | $23.65 | $24.02 | +1.6% | +0.8% | +0.6% | +0.9% | +0.6% | +1.9% |
| Mar 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $21.06 | $21.06 | +0.0% | -7.3% | -3.5% | -1.7% | -2.4% | +8.2% |
| Mar 2 | Credit Suisse | Maintains | Outperform → Outperform | — | $18.44 | $20.20 | +9.5% | +17.3% | +17.8% | +16.4% | +14.9% | +15.3% |
| Mar 2 | Barclays | Maintains | Overweight → Overweight | — | $18.44 | $20.20 | +9.5% | +17.3% | +17.8% | +16.4% | +14.9% | +15.3% |
| Jan 24 | Barclays | Maintains | Overweight → Overweight | — | $18.73 | $18.83 | +0.5% | -1.4% | -0.3% | +1.9% | +2.1% | +0.5% |
| Dec 14 | Baird | Downgrade | Outperform → Neutral | — | $17.40 | $17.05 | -2.0% | -6.4% | -5.7% | -7.1% | -7.1% | -6.3% |
| Nov 14 | Credit Suisse | Maintains | Outperform → Outperform | — | $14.65 | $14.54 | -0.8% | -0.1% | +6.3% | +2.5% | -3.3% | +2.9% |
| Oct 6 | Barclays | Maintains | Overweight → Overweight | — | $13.95 | $13.91 | -0.3% | -2.3% | -6.0% | -10.0% | -10.8% | -14.1% |
No insider trades available.
8-K · 1.01
!! High
Certara, Inc. -- 8-K 1.01: Material Agreement
Certara acquired Veristat, LLC for $100 million, expanding its regulatory and clinical trial solutions capabilities through this strategic acquisition.
Apr 22
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
CERT's departure of a key executive signals potential leadership instability and strategy uncertainty, likely pressuring the stock until succession clarity emerges and investor confidence in continuity strengthens.
Mar 31
8-K
Certara, Inc. -- 8-K Filing
Certara reported modest 3% Q4 revenue growth to $103.6M with declining adjusted EBITDA, guiding 2026 revenue growth of 0-4% and adjusted EPS of $0.44-$0.48, signaling slowing momentum.
Feb 26
Data updated apr 25, 2026 12:48am
· Source: massive.com